Halozyme Therapeutics, Inc. $HALO Position Decreased by Victory Financial Group LLC

Victory Financial Group LLC reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 69.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,169 shares of the biopharmaceutical company’s stock after selling 7,347 shares during the period. Victory Financial Group LLC’s holdings in Halozyme Therapeutics were worth $350,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of HALO. Roman Butler Fullerton & Co. purchased a new position in Halozyme Therapeutics in the third quarter worth $489,000. Oppenheimer & Co. Inc. increased its position in shares of Halozyme Therapeutics by 39.6% during the third quarter. Oppenheimer & Co. Inc. now owns 22,013 shares of the biopharmaceutical company’s stock worth $2,430,000 after purchasing an additional 6,241 shares in the last quarter. Verdence Capital Advisors LLC increased its position in shares of Halozyme Therapeutics by 21.5% during the third quarter. Verdence Capital Advisors LLC now owns 15,172 shares of the biopharmaceutical company’s stock worth $1,675,000 after purchasing an additional 2,684 shares in the last quarter. Westover Capital Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the third quarter worth $224,000. Finally, Apollon Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at $585,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on HALO shares. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. HC Wainwright upped their target price on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st. JPMorgan Chase & Co. increased their price target on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Finally, Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average target price of $99.55.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Matthew Posard sold 5,230 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $108.54, for a total value of $567,664.20. Following the transaction, the director directly owned 53,609 shares of the company’s stock, valued at approximately $5,818,720.86. This represents a 8.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 125,852 shares of company stock worth $13,538,046. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Up 0.9%

NASDAQ:HALO opened at $131.18 on Friday. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $132.55. The company has a market cap of $14.89 billion, a PE ratio of 26.38, a P/E/G ratio of 0.49 and a beta of 0.88. The company’s 50 day moving average is $113.21 and its two-hundred day moving average is $83.16.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter last year, the company posted $1.54 earnings per share. The business’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.